Results 121 to 130 of about 296,469 (371)
Chronic hepatitis C virus (HCV) infection can now be treated with oral directly acting antiviral agents, either with or without ribavirin (RBV). Virologic relapse after treatment can occur, and in some studies was more common in cirrhotic subjects.
Eric G. Meissner +11 more
semanticscholar +1 more source
Enhancing CHO cell recombinant protein production using a perfusion‐directed host evolution approach
Abstract Clonally derived cell lines generated from Chinese hamster ovary (CHO) cells encounter numerous stressors when cultured in high‐intensity perfusion bioreactors leading to poor process performance. To circumvent this, the ability of CHO cells to adapt to different culture environments was exploited. Here host cells were selected in the presence
Peter Amaya +7 more
wiley +1 more source
Efficacy and Safety of In-Asia-manufactured Interferon Alpha-2b in Combination with Ribavirin for Therapy of Naïve Chronic Hepatitis C Patients: a Multicenter, Prospective, Open-Label Trial [PDF]
Background: An open-label, multi center and non-comparative study was conducted to evaluate the efficacy and safety of a more affordable in-Asia-manufactured interferon á-2b product in combination with ribavirin to treat naïve chronic hepatitis C ...
Akbar, N. (Nurul) +8 more
core +1 more source
Non-Hodgkin's Lymphoma as an Extrahepatic Manifestation after Achieving Sustained Virologic Response for Hepatitis C Viral Infection [PDF]
Mihaela Ghioca +9 more
openalex +1 more source
Dynamics of natural killer cell function upon recurrent stimulation
Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One +4 more
wiley +1 more source
Background This is a real-world evidence study that aims to analyze the efficacy, tolerability and safety profile of paritaprevir/ombitasvir/ritonavir and dasabuvir, in patients with renal impairment.
Elena Laura Iliescu +2 more
doaj +1 more source
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation [PDF]
Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation. We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha‐2b plus ribavirin (Peg‐IFN‐α2b/RBV ...
Al‐Osaimi, Abdullah MS +11 more
core +1 more source
For biofuels production, hemicellulose pre‐hydrolysate is considered as an attractive feedstock rich in fermentable sugars. The pre‐hydrolysate derived from lignocellulosic biomass comprises, along with sugars, several inhibitors which can hamper its efficient conversion.
Mariem Theiri +3 more
wiley +1 more source
BACKGROUND AND OBJECTIVES: Evidence suggests that sustained virologic response to interferon treatment decreases incidence of hepatocellular carcinoma in patients with hepatitis C virus cirrhosis.
Nelson Cheinquer +3 more
doaj +1 more source
New virologic tools for management of chronic hepatitis B and C.: New Virological Tools [PDF]
International audienceMolecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze
Chevaliez, Stéphane +2 more
core +3 more sources

